Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETRA study of saruparib alone and in combination in advanced solid malignancies
2022-502856-29-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label trial of saruparib in Nonhematologic neoplasms (5 arms), sponsored by AstraZeneca. Primary endpoint: Safety and tolerability. Planned start Jul 2021; status: authorised.
02
Drugs
saruparib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2022-502856-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502856-29-00.